With the continuous disclosure of the 2016 annual report of multinational pharmaceutical companies, their R&D investment has also surfaced one by one. While sales continued to grow, Roche, Johnson & Johnson, and Novartis's R&D also went hand in hand. The Big Three had a combined R&D investment of over $30 billion. Where is the money, and where is the money? What are the key research and development varieties?
Hundreds of feet of hoes - the top 10 research and development investment is still awesome
Innovation is one of the core drivers of enterprise development. A series of "blockbusters" spawned by new drug research and development have brought huge economic benefits to a number of multinational giants. At the same time, multinational pharmaceutical companies, as leaders in the global pharmaceutical industry, continue to place R&D in a pivotal position. 
The top 10 global pharmaceutical companies still maintain high R&D investment in 2016, which is inextricably linked to the global environment in which many “blockbuster†drug patents expire. From the top ten research and development investment, most companies' R&D investment has increased, and only GlaxoSmithKline and Abbott have declined. Roche, Johnson & Johnson and Novartis ranked the top three with US$11.955 billion, US$9.095 billion and US$9.039 billion, respectively.
Where is the sword? The 3 giants have their own killers.
R & D investment is about "10 billion", and Roche, Johnson & Johnson, and Novartis are particularly prominent among multinational pharmaceutical companies. There are specializations in the industry, and the strengths of the Big Three in the research and development field are also different. It can be said that each has its own killer.
NO1. Roche - aiming at the dominance of multiple sclerosis
Compact Air Hose Reel,Retractable Air Hose Reel,Retractable Air Compressor Hose,Small Retractable Air Hose Reel
NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.hosereelqikai.com